The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition - Archive ouverte HAL Access content directly
Journal Articles Bulletin du Cancer Year : 2018

The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition

, , , , , , , , , , , , , , , , , , , , (1) ,
1
Jessica Moretta
  • Function : Author
Pascaline Berthet
  • Function : Author
Valerie Bonadona
  • Function : Author
Olivier Caron
  • Function : Author
Odile Cohen-Haguenauer
  • Function : Author
Chrystelle Colas
  • Function : Author
Carole Corsini
  • Function : Author
Veronica Cusin
  • Function : Author
Antoine de Pauw
Capucine Delnatte
  • Function : Author
Sophie Dussart
  • Function : Author
Christophe Jamain
  • Function : Author
Michel Longy
  • Function : Author
Elisabeth Luporsi
  • Function : Author
Christine Maugard
  • Function : Author
Tan Dat Nguyen
  • Function : Author
Pascal Pujol
Dominique Vaur
  • Function : Author
Nadine Andrieu
  • Function : Author
  • PersonId : 837335
Christine Lasset
  • Function : Author
Grp Genetique Canc Unicanc
  • Function : Author

Abstract

Introduction > Next generation sequencing allows the simultaneous analysis of large panel of genes for families or individuals with a strong suspicion of hereditary breast and/or ovarian cancer (HBOC). Because of lack of guidelines, several panels of genes potentially involved in HBOC were designed, with large disparities not only in their composition but also in medical care offered to mutation carriers. Then, homogenization in practices is needed. Methods > The French Genetic and Cancer Group (GGC) - Uniconcer conducted an exhaustive bibliographic work on 18 genes of interest. Only publications with unbiased risk estimates were retained. Results > The expertise of each 18 genes was based on clinical utility criteria, i.e. a relative risk of cancer of 4 and more, available medical tools for screening and prevention of mutation carriers, and pre-symptomatic genetic tests for relatives. Finally, 13 genes were selected to be included in a HBOC diagnosis gene panel: BRCA1, BRCA2, PALB2, TP53, CDPH1, PTEN, RAD51C, RAD51D, MLH1, MSH2, MSH6, PMS2, EPCAM. The reasons for excluding NBN, RAD51B, CHEK2, STK11, ATM, BARD1, BRIP1 from the HBOC diagnosis panel are presented. Screening, prevention and genetic counselling guidelines were detailed for each of the 18 genes. Discussion > Due to the rapid increase in knowledge, the GGC has planned a yearly update of the bibliography to take into account new findings. Furthermore, genetic-epidemiological studies are being initiated to better estimate the cancer risk associated with genes which are not yet included in the HBOC diagnosis panel.
Not file

Dates and versions

hal-02146849 , version 1 (04-06-2019)

Identifiers

Cite

Jessica Moretta, Pascaline Berthet, Valerie Bonadona, Olivier Caron, Odile Cohen-Haguenauer, et al.. The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition. Bulletin du Cancer, 2018, 105 (10), pp.907-917. ⟨10.1016/j.bulcan.2018.08.003⟩. ⟨hal-02146849⟩
52 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More